0  0%
Previous Close 1.25
Open 1.25
Price To Book 5.95
Market Cap 67,064,086
Shares 53,651,269
Volume 48,540
Short Ratio
Av. Daily Volume 371,694

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data presented at ECCMID April 13, 2019.
SCY-078 - oral - CARES
Candida Auris
Phase 2 trial initiated 3Q 2018.
Ibrexafungerp (SCY-078)
Invasive aspergillosis
Phase 3 data due 1H 2020.
SCY-078 - oral ibrexafungerp - VANISH
Vulvovaginal candidiasis (VVC)
Phase 3 open label interim data released January 30, 2019 - 11/17 partial or complete responses. Data to be presented at ECCMID April 16, 2019.
SCY-078 - oral (FURI)
Invasive candidiasis
Phase 3 trial to commence 2Q 2019.
SCY-078 - ibrexafungerp
Recuurent Vulvovaginal candidiasis (VVC)

Latest News

  1. X-Biotix Therapeutics Joins Antimicrobials Working Group
  2. World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
  3. Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
  4. Imagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop
  5. SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
  6. Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
  7. SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
  8. SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
  9. Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
  10. Scynexis: 1Q Earnings Snapshot
  11. SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update
  12. Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  13. SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
  14. SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
  15. SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call
  16. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  17. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  18. SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
  19. SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
  20. SCYNEXIS, Inc. to Present at Upcoming Investor Conferences